<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729664</url>
  </required_header>
  <id_info>
    <org_study_id>CA210-001</org_study_id>
    <secondary_id>MDX1105-01</secondary_id>
    <nct_id>NCT00729664</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose (MDX1105-01)</brief_title>
  <acronym>Anti-PDL1</acronym>
  <official_title>A Phase 1, Multidose Study of BMS-936559 (MDX-1105) Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Collection of survival data, evaluation of PDL-1 expression in tumors, and evaluation of
      PD-L1 receptor occupancy in peripheral blood has been added.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, multicenter, dose escalation and multidose study of MDX-11-5, a fully
      human monoclonal IgG4 antibody targeting the Programed Death-Ligand 1 (PD-L1).

      The study will consist of 3 periods: Screening (up to 28 days), Treatment (up to 16 six-week
      cycles), and Follow-up (up to 6 months).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, maximum tolerated dose (MTD) and dose-limiting toxicity(DLT)of MDX-1105</measure>
    <time_frame>Weekly</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, maximum tolerated dose (MTD) and dose-limiting toxicity(DLT)of MDX-1105</measure>
    <time_frame>Bi-weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy in solid tumors on the basis of objective responses</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">281</enrollment>
  <condition>Cancer, Multiple Indications</condition>
  <arm_group>
    <arm_group_label>Anti-PDL-1 antibody (Arm 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-936559 (MDX-1105)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-PDL-1 antibody (Arm 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-936559 (MDX-1105)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-PDL-1 antibody (Arm 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-936559 (MDX-1105)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-PDL-1 antibody (Arm 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-936559 (MDX-1105)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-PDL-1 antibody (Arm 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-936559 (MDX-1105)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-PDL-1 antibody</intervention_name>
    <description>Solution, Intravenous, 0.1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response</description>
    <arm_group_label>Anti-PDL-1 antibody (Arm 1)</arm_group_label>
    <other_name>BMS-936559</other_name>
    <other_name>MDX 1105</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-PDL-1 antibody</intervention_name>
    <description>Solution, Intravenous, 0.3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response</description>
    <arm_group_label>Anti-PDL-1 antibody (Arm 2)</arm_group_label>
    <other_name>BMS-936559</other_name>
    <other_name>MDX 1105</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-PDL-1 antibody</intervention_name>
    <description>Solution, Intravenous, 1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response</description>
    <arm_group_label>Anti-PDL-1 antibody (Arm 3)</arm_group_label>
    <other_name>BMS-936559</other_name>
    <other_name>MDX 1105</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-PDL-1 antibody</intervention_name>
    <description>Solution, Intravenous, 3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response</description>
    <arm_group_label>Anti-PDL-1 antibody (Arm 4)</arm_group_label>
    <other_name>BMS-936559</other_name>
    <other_name>MDX 1105</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-PDL-1 antibody</intervention_name>
    <description>Solution, Intravenous, 10 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response</description>
    <arm_group_label>Anti-PDL-1 antibody (Arm 5)</arm_group_label>
    <other_name>BMS-936559</other_name>
    <other_name>MDX 1105</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1

          -  The malignancies include relapsed/refractory renal cell carcinoma, non-small cell lung
             cancer, colorectal adenocarcinoma, malignant melanoma, advanced/metastatic epithelial
             ovarian cancer, gastric cancer, pancreatic cancer and breastcancer

          -  Must have measurable disease

        Exclusion Criteria:

          -  Prior therapy with an anti-PD 1, anti-PDL 1, or anti-Cytotoxic T-Lymphocyte Antigen 4
             antibody (or any other agents that target T-cell co-stimulation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Angeles Clinic &amp; Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants, Pa</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University Of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2008</study_first_submitted>
  <study_first_submitted_qc>August 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2008</study_first_posted>
  <last_update_submitted>September 3, 2015</last_update_submitted>
  <last_update_submitted_qc>September 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

